FK506结合蛋白65在肝细胞肝癌组织间质细胞中的表达及临床意义

Expression of FK506 binding protein 65 in stroma cells of hepatocellular carcinoma tissues and its clinical significances

目的:探讨FK506结合蛋白65(FKBP65)在肝细胞肝癌(简称肝癌)组织中的表达及其与肝癌临床病理特征和预后的关系。方法:应用免疫组化方法检测147例肝癌标本中FKBP65表达情况,分析FKBP65的表达水平与患者临床病理指标的相关性。采用Kaplan-Meier法对肝癌患者术后生存及无复发生存进行单因素分析;采用Cox回归风险比例模型对肝癌患者术后总生存及无复发生存进行多因素分析。结果:FKBP65在肝癌组织肿瘤细胞和间质细胞中均有表达。肝癌组织间质细胞中FKBP65的表达与肿瘤直径正相关(P=0.001)。单因素分析表明,肝癌组织间质细胞中FKBP65高表达组患者总生存率及无复发生存率明显低于低表达组(P=0.002,P=0.011)。多因素分析表明,FKBP65在肝癌组织间质细胞中高表达是肝癌患者术后总生存(HR=2.676,95%CI 1.463～4.859)和无复发生存(HR=1.731,95%CI 1.032～2.905)的独立危险因素。结论:FKBP65在肝癌组织间质细胞中高表达与肝癌不良预后相关。

Objective:To explore the expression of FK506 binding protein 65 (FKBP65) in hepatocellular carcinoma (HCC) tissues and evaluate the prognosis value of FKBP65 in HCC. Methods:The expression of FKBP65 was detected by immunohistochemical staining in 147 HCC tissue samples. The correlation between FKBP65 and other clinical and pathological characteristics was analyzed. Univariate Kaplan-Meier analysis and multivariate Cox proportional hazard regression model analysis were performed to investigate the overall survival and recurrence free survival. Results:FKBP65 was expressed both in the tumor cells and stroma cells in the HCC tissues. The FKBP65 expression in stroma cells was positively associated with tumor sizes ( P=0.001). The univariate analysis showed that the patients with high FKBP65 expression in stroma cells group had lower overall survival and recurrence free survival compared with low FKBP65 expression group (P=0.002,P =0.011). The Multivariate analysis showed that the high FKBP65 expression in stroma cells was an independent risk factor for the overall survival (HR=2.676, 95%CI 1.463-4.859) and recurrence free survival (HR=1.731, 95%CI 1.032-2.905). Conclusions:High FKBP65 expression in stroma cells of the HCC tissue might be associated with poor clinical outcomes.